150 related articles for article (PubMed ID: 36440216)
21. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract][Full Text] [Related]
22. Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis.
Korpershoek E; Koffy D; Eussen BH; Oudijk L; Papathomas TG; van Nederveen FH; Belt EJ; Franssen GJ; Restuccia DF; Krol NM; van der Luijt RB; Feelders RA; Oldenburg RA; van Ijcken WF; de Klein A; de Herder WW; de Krijger RR; Dinjens WN
J Clin Endocrinol Metab; 2016 Feb; 101(2):453-60. PubMed ID: 26670126
[TBL] [Abstract][Full Text] [Related]
23. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.
Dénes J; Swords F; Rattenberry E; Stals K; Owens M; Cranston T; Xekouki P; Moran L; Kumar A; Wassif C; Fersht N; Baldeweg SE; Morris D; Lightman S; Agha A; Rees A; Grieve J; Powell M; Boguszewski CL; Dutta P; Thakker RV; Srirangalingam U; Thompson CJ; Druce M; Higham C; Davis J; Eeles R; Stevenson M; O'Sullivan B; Taniere P; Skordilis K; Gabrovska P; Barlier A; Webb SM; Aulinas A; Drake WM; Bevan JS; Preda C; Dalantaeva N; Ribeiro-Oliveira A; Garcia IT; Yordanova G; Iotova V; Evanson J; Grossman AB; Trouillas J; Ellard S; Stratakis CA; Maher ER; Roncaroli F; Korbonits M
J Clin Endocrinol Metab; 2015 Mar; 100(3):E531-41. PubMed ID: 25494863
[TBL] [Abstract][Full Text] [Related]
26. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
27. A Novel Phenotype of Germline Pathogenic Variants in
Chang X; Li Z; Ma X; Cui Y; Chen S; Tong A
Front Endocrinol (Lausanne); 2020; 11():558. PubMed ID: 32973681
[No Abstract] [Full Text] [Related]
28. [Multiple Endocrine Neoplasia].
Uchino S; Ito A
Gan To Kagaku Ryoho; 2019 Jul; 46(7):1114-1118. PubMed ID: 31296813
[TBL] [Abstract][Full Text] [Related]
29. The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation.
Carey ET; Ferreira V; Shum E; Zhou F; Sabari JK
Clin Lung Cancer; 2022 Jan; 23(1):e1-e4. PubMed ID: 34246541
[TBL] [Abstract][Full Text] [Related]
30. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
31. Genetics of pheochromocytoma and paraganglioma.
Wachtel H; Fishbein L
Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):283-290. PubMed ID: 33764930
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
33. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.
Pires C; Marques IJ; Dias D; Saramago A; Leite V; Cavaco BM
Endocrine; 2021 Sep; 73(3):588-597. PubMed ID: 33683595
[TBL] [Abstract][Full Text] [Related]
34. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
35. Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
Iyevleva AG; Aleksakhina SN; Sokolenko AP; Baskina SV; Venina AR; Anisimova EI; Bizin IV; Ivantsov AO; Belysheva YV; Chernyakova AP; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2022 Apr; 192(2):283-291. PubMed ID: 35020107
[TBL] [Abstract][Full Text] [Related]
36. Is
De Silva DL; Winship I
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32900738
[TBL] [Abstract][Full Text] [Related]
37. Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma.
Lipton L; Fleischmann C; Sieber OM; Thomas HJ; Hodgson SV; Tomlinson IP; Houlston RS
Cancer Lett; 2003 Oct; 200(2):149-52. PubMed ID: 14568168
[TBL] [Abstract][Full Text] [Related]
38. Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with
Gąsior-Perczak D; Kowalik A; Kopczyński J; Macek P; Niemyska K; Walczyk A; Gruszczyński K; Siołek M; Dróżdż T; Kosowski M; Pałyga I; Przybycień P; Wabik O; Góźdź S; Kowalska A
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398207
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
[TBL] [Abstract][Full Text] [Related]
40. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.
Marx SJ; Agarwal SK; Kester MB; Heppner C; Kim YS; Skarulis MC; James LA; Goldsmith PK; Saggar SK; Park SY; Spiegel AM; Burns AL; Debelenko LV; Zhuang Z; Lubensky IA; Liotta LA; Emmert-Buck MR; Guru SC; Manickam P; Crabtree J; Erdos MR; Collins FS; Chandrasekharappa SC
Recent Prog Horm Res; 1999; 54():397-438; discussion 438-9. PubMed ID: 10548885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
